148 related articles for article (PubMed ID: 1441695)
1. [Pimobendan (UDCG 115 BS) in long-term therapy of chronic heart failure].
Bergler-Klein J; Globits S; Stefenelli T; Mayr H; Porenta G; Sochor H; Glogar D
Z Kardiol; 1992 Oct; 81(10):546-52. PubMed ID: 1441695
[TBL] [Abstract][Full Text] [Related]
2. [Acute and long-term effects of pimobendan (UD-CG 115) in NYHA II and III heart failure. Results of a randomized multicenter double-blind study].
Assmann I; Kassel P; Duck HG; Fiehring H; Morgan P; Schmidt PK; Höfs T; Nehmiz G
Z Kardiol; 1991 Nov; 80(11):687-94. PubMed ID: 1792811
[TBL] [Abstract][Full Text] [Related]
3. [Reduction in left ventricular volume and improvement in hemodynamics following intravenous administration of pimobendan (UDGG 115 BS) in dilated cardiomyopathy].
Permanetter B; Sebening H; Busch U; Lutilsky L
Z Kardiol; 1990 Aug; 79(8):565-72. PubMed ID: 2220013
[TBL] [Abstract][Full Text] [Related]
4. Acute and long-term hemodynamic effects of pimobendan (UD-CG 115 BS) in comparison with captopril.
Hauf GF; Grom E; Jähnchen E; Roskamm H
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S49-56. PubMed ID: 2478793
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, randomized, double-blind, placebo-controlled trial of pimobendan, a new cardiotonic and vasodilator agent, in patients with severe congestive heart failure.
Katz SD; Kubo SH; Jessup M; Brozena S; Troha JM; Wahl J; Cohn JN; Sonnenblick EH; LeJemtel TH
Am Heart J; 1992 Jan; 123(1):95-103. PubMed ID: 1729854
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-term treatment with pimobendan on neurohumoral factors in patients with non-ischemic chronic moderate heart failure.
Sasaki T; Kubo T; Komamura K; Nishikimi T
J Cardiol; 1999 Jun; 33(6):317-25. PubMed ID: 10396705
[TBL] [Abstract][Full Text] [Related]
7. [Acute and chronic effects of UDCG 115 BS (pimobendan) in patients with advanced myocardial failure].
Permanetter B; Baumann G; Wirtzfeld A; Günes S; Stinshoff M; Klein G
Z Kardiol; 1989 May; 78(5):335-42. PubMed ID: 2660451
[TBL] [Abstract][Full Text] [Related]
8. Persistent hemodynamic effects without long-term clinical benefits in response to oral piroximone (MDL 19,205) in patients with congestive heart failure.
Petein M; Levine TB; Cohn JN
Circulation; 1986 Mar; 73(3 Pt 2):III230-6. PubMed ID: 3510778
[TBL] [Abstract][Full Text] [Related]
9. Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure.
Baumann G; Ningel K; Permanetter B
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S23-30. PubMed ID: 2478788
[TBL] [Abstract][Full Text] [Related]
10. [Acute hemodynamic effects of pimobendan and captopril: a comparative study in the same patients with chronic heart failure].
Tsuda T; Izumi T; Kodama M; Hanawa H; Ohshima M; Takahashi M; Suzuki M; Aizaki T; Uchiyama H; Shibata A
J Cardiol; 1992; 22(4):721-9. PubMed ID: 1343639
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of pimobendan in moderate heart failure. A double-blind parallel 6-month comparison with enalapril. The Pimobendan-Enalapril Study Group.
Remme WJ; Krayenbühl HP; Baumann G; Frick MH; Haehl M; Nehmiz G; Baiker W
Eur Heart J; 1994 Jul; 15(7):947-56. PubMed ID: 7925517
[TBL] [Abstract][Full Text] [Related]
12. Correlations between the cardiovascular effects of pimobendan and plasma concentrations of the parent compound and of its major active metabolite, UD-CG 212 CL, in patients with congestive heart failure.
Hagemeijer F; Roth W; Brand HJ
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S57-64. PubMed ID: 2478794
[TBL] [Abstract][Full Text] [Related]
13. Hemodynamic effects of intravenous pimobendan in patients with left ventricular dysfunction.
Remme WJ; Wiesfeld AC; Look MP; Kruyssen HA
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S41-4. PubMed ID: 2478791
[TBL] [Abstract][Full Text] [Related]
14. The calcium channel blocker felodipine attenuates the positive hemodynamic effects of the beta-blocker metoprolol in severe dilated cardiomyopathy--a prospective, randomized, double-blind and placebo-controlled study with invasive hemodynamic assessment.
Braun M; Edelmann F; Knapp M; Schön S; Schwencke C; Simonis G; Borst M; Weinbrenner C; Strasser RH
Int J Cardiol; 2009 Feb; 132(2):248-56. PubMed ID: 18579230
[TBL] [Abstract][Full Text] [Related]
15. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
Kubo SH; Gollub S; Bourge R; Rahko P; Cobb F; Jessup M; Brozena S; Brodsky M; Kirlin P; Shanes J
Circulation; 1992 Mar; 85(3):942-9. PubMed ID: 1537130
[TBL] [Abstract][Full Text] [Related]
16. [Lack of symptomatic and long-term hemodynamic effects of prazosin in chronic heart failure. Double-blind, randomized study over one year].
Reifart N; Schmidt-Moritz AD; Nadj M; Kaltenbach M; Bussmann WD
Z Kardiol; 1985 Apr; 74(4):205-12. PubMed ID: 3923726
[TBL] [Abstract][Full Text] [Related]
17. Use of pimobendan in the management of heart failure.
Fuentes VL
Vet Clin North Am Small Anim Pract; 2004 Sep; 34(5):1145-55. PubMed ID: 15325474
[TBL] [Abstract][Full Text] [Related]
18. Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan.
Kato K
Cardiology; 1997; 88 Suppl 2():28-36. PubMed ID: 9142433
[TBL] [Abstract][Full Text] [Related]
19. The effect of enalapril on cardiac arrhythmias in patients with congestive heart failure.
Sniezek-Maciejewska M; Czarnecka D; Mroczek-Czernecka D; Kawecka-Jaszcz K
Cor Vasa; 1992; 34(5-6):382-9. PubMed ID: 1285055
[TBL] [Abstract][Full Text] [Related]
20. Effects of pimobendan (UD-CG 115 BS) on left ventricular inotropic state in conscious dogs and in patients with heart failure.
Pouleur H; Hanet C; Schröder E; Col J; Van Mechelen H; Etienne J; Rousseau MF
J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S18-22. PubMed ID: 2478787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
